The 15th Annual Pain Therapeutics Summit
Categories:
Prescription Medicines, Events
NOVEMBER 1–2, 2021 | WASHINGTON, DC
The Potential Role for Psychedelic Drugs in the Treatment of Chronic Pain
Psychedelic drugs are currently being evaluated for their efficacy in treating several neuropsychiatric conditions and may have a potential role as treatments for chronic pain. This panel session will explore the potential role that psychedelic drugs may play in treating chronic pain and related symptoms. A panel Q&A session with speakers will follow the presentations.
Moderator
Judy Ashworth, MD, Vice President, Rx Strategic Services and Chief Medical Officer, Pinney Associates
Presenters
Historical evidence and rationale for developing psychedelic drugs as analgesics
Ryan Lanier, PhD, Director, Clinical Development and Abuse Liability, Pinney Associates
Challenges designing and conducting chronic pain trials with psychedelics
Robert Dworkin, PhD, Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry Professor, Center for Heath + Technology; Director, Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION), a public-private partnership with the FDA; University of Rochester School of Medicine and Dentistry
Abuse potential related science and regulatory perspectives for psychedelic drug product development and post-approval challenges
Jack Henningfield, PhD, Vice President, Research, Health Policy, and Abuse Liability, Pinney Associates
